Experiences with
Lung transplant4,790 public posts
Want to take advantage of all our features? Just log in!
or
Why I’m participating in the next cancer voices summit
Were you aware that the original 2020 Federal Budget cut out funding for lung cancer search?
A concerted effort by patients, families, clinicians, advocates and lung cancer foundations got lung cancer specific funding restored.
That’s important because lung cancer is the most frequent cause of cancer
(FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced NSCLC
On May 29th, 2020, the Food and Drug Administration (FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in EGFR called exon 19 deletions or exon 21 L858R mutations. The FDA
FDA Approves nivolumab Plus ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC
This is the eighth drug approval in two months, please email support@go2foundation.org if you have any questions about any of these recent approvals.
On May 26, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab), Yervoy (ipilimumab), and two cycles of platinum-doublet
FDA Approves Brigatinib for ALK-positive Metastatic NSCLC
On May 22, 2020, the Food and Drug Administration (FDA) approved Alunbrig (brigatinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in ALK. The FDA based their approval on the results of the clinical trial ALTA 1L which showed that patients receiving